OKYO Pharma Limited ADR OKYO 深 沪
等待开盘 10-20 09:30:00 美东时间
2.24
+0.130
+6.16%
华盛通- 最 高2.25
- 今 开2.11
- 成交量 20.17万股
- 最 低 2.0854
- 昨 收 2.11
- 总市值 8424.80万
- 52周最高 3.349
- 市盈率 静 --
- 换手率 0.54%
- 52周最低 0.9016
- 委 比 -21.59%
- 总股本 3761.07万
- 历史最高 7.00
- 量 比 0.80
- 振 幅 7.80%
- 历史最低 0.8075
- 每 手 1
- 风险率 0.65%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多OKYO Pharma’s Chairman Increases Stake with New Share Acquisition
An announcement from OKYO Pharma Limited Sponsored ADR ( ($OKYO) ) is now avail...
10-16 20:57
OKYO Pharma Says Executive Chairman Gabriele Cerrone Acquires 210K Of Company Shares On NASDAQ; Now Holds 10.38M Shares
OKYO Pharma Limited (NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod to treat neuropathic corneal pain (NCP), an ocular condition associated with chronic and often
10-16 20:33
OKYO Pharma Announces Chairman and Founder Acquires Shares
OKYO Pharma Limited (NASDAQ: OKYO) announces that Panetta Partners Limited, an entity associated with its Executive Chairman Gabriele Cerrone, has acquired 210,000 ordinary shares, increasing his total holding to 10,382,677 shares. The company is developing urcosimod, a long-acting drug candidate for treating neuropathic corneal pain (NCP) and dry eye disease, which has shown significant results in Phase 2 trials. OKYO is focused on innovative th...
10-16 12:30
美股大行评级 | 升至450美元，瑞穗上调特斯拉目标价；富国银行上调CoreWeave至"超配"，目标价升至170美元
今日重点评级关注：Guggenheim：维持MBX Biosciences"买入"评级，目标价从44美元升至84美元；Oppenheimer：维持MBX Biosciences"跑赢大市"评级，目标价从38美元升至80美元
09-24 10:23
OKYO Pharma Announces Plans For Next Stage Of Clinical Development For Lead Drug Candidate, Urcosimod, To Treat Neuropathic Corneal Pain
OKYO Pharma Limited (NASDAQ:OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod to treat neuropathic corneal pain (NCP), an ocular condition associated with chronic and often severe
09-22 20:37
OKYO Pharma Announces Registration Pathway with 100 Patient Multi-Center Clinical Trial of Urcosimod in Neuropathic Corneal Pain
OKYO Pharma announced plans to advance the next stage of clinical development for its drug candidate urcosimod to treat neuropathic corneal pain (NCP). Following positive Phase 2 trial results showing 75% of patients experienced significant pain reduction, the company is conducting a multiple-ascending-dose trial to enroll approximately 100 NCP patients, identify the optimal dose for future trials, and further study urcosimod's properties. Additi...
09-22 12:30
OKYO Pharma Receives $1.9 Million in Non-Dilutive Funding to Accelerate Development of Urcosimod for Neuropathic Corneal Pain
OKYO Pharma Limited received $1.9 million in non-dilutive funding to accelerate the development of urcosimod, its lead drug candidate for treating neuropathic corneal pain (NCP), a debilitating condition with no FDA-approved therapy. The funding supports clinical milestones, R&D expansion, and regulatory progress, enabling the company to pursue its mission without diluting shareholder value. Urcosimod, a lipid-conjugated chemerin peptide agonist,...
07-17 13:00
OKYO Pharma Announces Top-Line Data From Recently Closed 18-Patient Phase 2 Trial Of Urcosimod To Treat NCP
After 12 weeks of treatment, 75% of per-protocol patients receiving 0.05% urcosimod showed greater than 80% reduction in neuropathic corneal pain (NCP), as measured by Visual Analogue Scale (VAS), demonstrating highly
07-16 21:22
OKYO Pharma to Present at the Bio International Convention
OKYO Pharma announced that its CEO, Dr. Gary S. Jacob, will present at the 2025 Bio International Convention in Boston about urcosimod, a drug candidate for treating neuropathic corneal pain (NCP). NCP causes severe eye discomfort due to nerve damage and inflammation, affecting tens of thousands globally. Urcosimod, a long-acting drug targeting eye inflammation and pain, showed significant results in Phase 2 trials for dry eye disease and is now ...
06-11 12:30
OKYO Pharma CEO to Present at Boston Drug Discovery Summit
OKYO Pharma Limited Sponsored ADR ( ($OKYO) ) has shared an update. On May 19, ...
05-19 19:27
